JP2025502383A5 - - Google Patents
Info
- Publication number
- JP2025502383A5 JP2025502383A5 JP2024542372A JP2024542372A JP2025502383A5 JP 2025502383 A5 JP2025502383 A5 JP 2025502383A5 JP 2024542372 A JP2024542372 A JP 2024542372A JP 2024542372 A JP2024542372 A JP 2024542372A JP 2025502383 A5 JP2025502383 A5 JP 2025502383A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutical formulation
- hydrogen
- alkyl
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263300538P | 2022-01-18 | 2022-01-18 | |
| US63/300,538 | 2022-01-18 | ||
| PCT/US2023/010565 WO2023141044A1 (en) | 2022-01-18 | 2023-01-11 | Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025502383A JP2025502383A (ja) | 2025-01-24 |
| JP2025502383A5 true JP2025502383A5 (https=) | 2026-01-20 |
Family
ID=87348890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024542372A Pending JP2025502383A (ja) | 2022-01-18 | 2023-01-11 | 代謝及び肝臓障害の処置のための医薬製剤及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250171499A1 (https=) |
| EP (1) | EP4466022A4 (https=) |
| JP (1) | JP2025502383A (https=) |
| KR (1) | KR20240136386A (https=) |
| CN (1) | CN118946368A (https=) |
| AR (1) | AR128285A1 (https=) |
| AU (1) | AU2023208627A1 (https=) |
| CA (1) | CA3248728A1 (https=) |
| MX (1) | MX2024008795A (https=) |
| TW (1) | TW202339789A (https=) |
| WO (1) | WO2023141044A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| WO2025209422A1 (en) * | 2024-04-01 | 2025-10-09 | Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. | Incretin analogs as glp-1, gip and glucagon receptor triple agonists and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3300721T4 (da) * | 2003-11-20 | 2025-03-03 | Novo Nordisk As | Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger |
| TWI705820B (zh) * | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| SG11202100112YA (en) * | 2018-07-23 | 2021-02-25 | Lilly Co Eli | Methods of using a gip/glp1 co-agonist for therapy |
| CA3204051A1 (en) * | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2024020388A1 (en) * | 2022-07-20 | 2024-01-25 | Viking Therapeutics, Inc. | Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders |
-
2023
- 2023-01-11 CN CN202380028118.2A patent/CN118946368A/zh active Pending
- 2023-01-11 AU AU2023208627A patent/AU2023208627A1/en active Pending
- 2023-01-11 JP JP2024542372A patent/JP2025502383A/ja active Pending
- 2023-01-11 US US18/729,459 patent/US20250171499A1/en active Pending
- 2023-01-11 CA CA3248728A patent/CA3248728A1/en active Pending
- 2023-01-11 MX MX2024008795A patent/MX2024008795A/es unknown
- 2023-01-11 KR KR1020247027089A patent/KR20240136386A/ko active Pending
- 2023-01-11 EP EP23743616.7A patent/EP4466022A4/en active Pending
- 2023-01-11 WO PCT/US2023/010565 patent/WO2023141044A1/en not_active Ceased
- 2023-01-17 TW TW112101927A patent/TW202339789A/zh unknown
- 2023-01-18 AR ARP230100109A patent/AR128285A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025502383A5 (https=) | ||
| US7371777B2 (en) | Cyclic compound and PPAR agonist | |
| US7687664B2 (en) | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | |
| US7105554B2 (en) | Benzylidene thiazolidinediones and their use as antimycotic agents | |
| JP2008509187A5 (https=) | ||
| US9782420B2 (en) | Method for treating eye diseases | |
| TW201908298A (zh) | 胺烷基苯並硫氮呯衍生物之用途 | |
| AU2023311214A1 (en) | Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders | |
| CN111315383A (zh) | 共享表位-钙网蛋白相互作用的小分子抑制剂和使用方法 | |
| TW201618763A (zh) | 用於預防及治療糖尿病之經取代之芳族化合物及醫藥組合物 | |
| CN101619061B (zh) | 氰基吡啶基取代的噁唑烷酮类化合物 | |
| US20050070565A1 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
| US10065984B2 (en) | Polymorphic forms of a steroid-like compound and methods for the preparation and use thereof | |
| KR20110028199A (ko) | 광학 활성 피페리딘 화합물의 개량된 제조방법 | |
| JP2008540427A (ja) | 置換β−ラクタム及び医薬におけるその使用 | |
| RU2024119883A (ru) | Фармацевтические составы и способы лечения метаболических и печеночных расстройств | |
| CA2425164C (en) | (4-acylaminopiperidin-1-yl)acetamides as neurokinin antagonists | |
| US20240182472A1 (en) | Indazole pyridone compounds and uses thereof | |
| WO2003070239A1 (en) | Benzylidene thiazolidinediones and their use as antimycotic agents | |
| JP5147071B2 (ja) | α−置換フェニルプロピオン酸誘導体 | |
| WO2006097809B1 (en) | Novel tyrosine derivatives | |
| JP2006509022A5 (https=) | ||
| US20220153767A1 (en) | Pharmaceutical crystal of contezolid acefosamil, preparation method therefor, and uses thereof | |
| US9737510B2 (en) | Indazole compounds and a process for the preparation thereof | |
| JP2023503470A5 (https=) |